Stocktoria
Electromed, Inc. ELMD
NYSE American · XASE · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2010-08-13
Electromed, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.0M | $54.7M | $48.1M | $41.7M | $35.8M | $32.5M | $31.3M | $28.3M | $25.9M | $23.0M |
| Gross profit | $50.0M | $41.7M | $36.5M | $31.4M | $27.3M | $25.2M | $23.8M | $21.8M | $20.6M | $17.9M |
| R&D expense | $996,000 | $656,000 | $916,000 | $1.4M | $1.7M | $1.1M | $583,311 | $251,443 | $596,876 | $380,392 |
| SG&A expense | $39.3M | $34.5M | $31.6M | $27.1M | $22.4M | $19.9M | $20.4M | $18.8M | $16.4M | $14.4M |
| Operating income | $9.7M | $6.6M | $4.0M | $3.0M | $3.1M | $5.1M | $2.8M | $2.7M | $3.6M | $3.1M |
| Income tax | $2.7M | $1.9M | $920,000 | $692,000 | $805,000 | $1.1M | $940,000 | $901,000 | $1.3M | $830,000 |
| Net income | $7.5M | $5.2M | $3.2M | $2.3M | $2.4M | $4.2M | $2.0M | $1.8M | $2.2M | $2.2M |
| EPS (diluted) | $0.85 | $0.58 | $0.36 | $0.26 | $0.27 | $0.47 | $0.23 | $0.21 | $0.26 | $0.27 |
| Operating cash flow | $11.4M | $9.1M | $1.3M | -$686,000 | $3.1M | $4.2M | $2.6M | $2.4M | $1.2M | $2.2M |
| Free cash flow | $11.1M | $8.8M | -$333,000 | -$2.1M | $2.8M | $3.4M | $1.3M | $1.9M | $572,358 | $1.6M |
| Cash & equivalents | $15.3M | $16.1M | $7.4M | $8.2M | $11.9M | $10.5M | — | — | — | — |
| Inventory | $3.3M | $3.7M | $4.2M | $3.2M | $2.1M | $3.1M | $2.6M | $2.5M | $2.6M | $2.5M |
| Total assets | $53.8M | $52.2M | $45.8M | $41.4M | $37.1M | $33.2M | $29.4M | $27.4M | $23.1M | $20.6M |
| Total liabilities | $10.6M | $7.7M | $8.1M | $7.2M | $4.7M | $3.0M | $3.7M | $4.7M | $4.0M | $4.2M |
| Shareholders' equity | $43.2M | $44.5M | $37.7M | $34.2M | $32.4M | $30.2M | $25.7M | $22.6M | $19.8M | $16.4M |
Growth · year-over-year · Revenue CAGR 12%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +17.0% | +13.8% | +15.4% | +16.5% | +10.1% | +3.7% | +10.6% | +9.5% | +12.5% | +18.5% |
| Net income growth | +46.3% | +62.7% | +37.4% | -2.4% | -43.2% | +110.1% | +8.1% | -17.9% | +0.8% | +102.5% |
| EPS growth | +46.6% | +61.1% | +38.5% | -3.7% | -42.6% | +104.3% | +9.5% | -19.2% | -3.7% | +107.7% |
| Free cash flow growth | +26.8% | — | — | -175.7% | -16.8% | +166.2% | -34.3% | +234.8% | -64.9% | -27.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001488917 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.